Award

75A50124C00001

BARDA WILL IMPLEMENT A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER PHASE 2 TRIAL IN THE US TO EVALUATE THE SAFETY AND EFFICACY OF NOVEL HOST-DIRECTED THERAPEUTIC CANDIDATES IN HOSPITALIZED ADULTS WITH ARDS.

About this data

Bounded ingest, not a census: 20,977 contract awards currently loaded (1,294 with full transaction history), per the scope in outlay.config.json. Totals are totals of the ingested set.
Dollar amounts are obligations — money the government has promised to pay, not cash already out the door. Agencies report this data themselves; the Defense Department publishes ~90 days late; the current budget year is still in progress. See methodology.
Source records republish silently; Outlay keeps its own append-only version archive from first pull onward. Post-publication revisions recorded so far: 0 awards (0 revisions). Revisions are routine (spending progresses, errors get corrected) and are not themselves evidence of anything.

Last ingest run #11 (failed) started Aug 5, 2026, 07:42 UTC — 0 awards, 0 details, 0 transactions.

Recipient: PPD DEVELOPMENT LP
Awarding agency: Department of Health and Human Services
Sub-agency: Office of Assistant Secretary for Preparedness and Response
Fiscal year: FY2024
Obligated (promised): $117,399,278
Total obligation (detail): $117,399,278
Potential value (ceiling): $222,126,308
Outlaid (paid out, linked File C): no linked financial data
Signed: Dec 15, 2023
Period of performance: Dec 15, 2023 – Sep 30, 2030
Competition: FULL AND OPEN COMPETITION
Offers received: 1
Solicitation: NEGOTIATED PROPOSAL/QUOTE
Pricing: COST PLUS INCENTIVE FEE
NAICS: 541714 — RESEARCH AND DEVELOPMENT IN BIOTECHNOLOGY (EXCEPT NANOBIOTECHNOLOGY)
Award type: DEFINITIVE CONTRACT

Structural flags (1)

Competed award, single offer received
These contracts were officially open for any company to compete, but only one company showed up. Sometimes only one company really can do the job; sometimes the contest was set up so only one could win.
extent_competed=A · number_of_offers_received=1
Rule single_bid_competed, methodology v1.2.0 — definition and caveats

Transactions (4)


0	Dec 15, 2023	—	$117,399,278	BARDA WILL IMPLEMENT A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER PHASE 2 TRIAL IN THE US TO EVALUATE THE SAFETY AND EFFICACY OF NOVEL HOST-DIRECTED THERAPEUTIC CANDIDATES IN HOSPITALIZED ADULTS WITH ARDS.
P00001	Aug 30, 2024	OTHER ADMINISTRATIVE ACTION	$0	BARDA WILL IMPLEMENT A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER PHASE 2 TRIAL IN THE US TO EVALUATE THE SAFETY AND EFFICACY OF NOVEL HOST-DIRECTED THERAPEUTIC CANDIDATES IN HOSPITALIZED ADULTS WITH ARDS.
P00002	Jul 11, 2025	OTHER ADMINISTRATIVE ACTION	$0	BARDA WILL IMPLEMENT A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER PHASE 2 TRIAL IN THE US TO EVALUATE THE SAFETY AND EFFICACY OF NOVEL HOST-DIRECTED THERAPEUTIC CANDIDATES IN HOSPITALIZED ADULTS WITH ARDS.
P00003	Nov 12, 2025	OTHER ADMINISTRATIVE ACTION	$0	BARDA WILL IMPLEMENT A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER PHASE 2 TRIAL IN THE US TO EVALUATE THE SAFETY AND EFFICACY OF NOVEL HOST-DIRECTED THERAPEUTIC CANDIDATES IN HOSPITALIZED ADULTS WITH ARDS.

Record history in our archive

Outlay keeps a content-hashed copy of this record from every pull. No post-publication revisions observed so far.

Aug 5, 2026, 07:40 UTCdetailfirst capture